News

Scientists created mini-brain models from LBD patients' stem cells, mimicking key disease features. Using these models, they screened nearly 1,300 FDA-approved drugs and identified four potential compounds to inhibit alpha-synuclein buildup.

Research suggests that rodents produce ultrasonic vocalizations (USVs) to influence particle movement, enhancing their olfactory reception. This finding challenges traditional views of rodent vocalizations as social cues.

Researchers have used cells from cord blood to recreate a functioning human immune system in mice.

The researchers argue that a sizable proportion of drugs and other compounds can bind to melanin pigments in the skin, leading to differences in how bioavailable and efficacious these drugs and other compounds are in people with varying skin tones.

Researchers have discovered that a novel combination therapy promotes cancer cell death and tumor regression in pancreatic cancer.

Understanding how "selfish" bacteria are could guide tailored treatments to combat antibiotic resistance.

A new gene therapy technology enables the non-invasive control of specific brain circuits, holding promise for studying the brain and finding treatments for neurological conditions.

Scientists developed a nanobody, NbE, that binds tightly to opioid receptors, blocking their activity. This could mitigate the severe side effects of opioids and lead to the creation of smaller, more effective molecules.

NUS Medicine researchers are exploring a gene therapy approach for epilepsy linked to the KCNA2 mutation. The therapy uses Gapmer antisense oligonucleotides to target faulty RNA, restoring potassium flow and reducing excessive neuron activity.

Researchers report that 94% of patients treated with the gene therapy eli-cel for cerebral adrenoleukodystrophy (CALD) have maintained neurological function six years post-treatment.